tiprankstipranks
Trending News
More News >
Control Bionics Ltd. (AU:CBL)
ASX:CBL
Australian Market
Advertisement

Control Bionics Ltd. (CBL) AI Stock Analysis

Compare
1 Followers

Top Page

AU:CBL

Control Bionics Ltd.

(Sydney:CBL)

Rating:48Neutral
Price Target:
AU$0.00
▼(-100.00%Downside)
Control Bionics Ltd. faces significant financial challenges with declining revenues and high losses, which are the most critical factors affecting its score. Despite technical indicators showing upward momentum, the overbought RSI signals potential volatility. The lack of profitability as indicated by the negative P/E ratio further weighs down the overall score.

Control Bionics Ltd. (CBL) vs. iShares MSCI Australia ETF (EWA)

Control Bionics Ltd. Business Overview & Revenue Model

Company DescriptionControl Bionics Ltd. (CBL) is a healthcare technology company specializing in assistive communication devices for individuals with speech and movement disabilities. Operating within the medical and assistive technology sectors, CBL develops and markets innovative products that enable users to communicate through brain-computer interface technology and electromyography, providing enhanced quality of life for those with conditions such as ALS, spinal cord injuries, and cerebral palsy.
How the Company Makes MoneyControl Bionics Ltd. makes money primarily through the sale of its assistive communication devices and related accessories. The company generates revenue by marketing its products directly to consumers, healthcare institutions, and through distribution partnerships. Key revenue streams include the NeuroNode technology, which combines brain-computer interface and electromyography to allow users to control devices with minimal muscle movement. The company may also engage in partnerships with healthcare providers and institutions for product trials and adoption, further contributing to its earnings.

Control Bionics Ltd. Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue5.13M5.44M4.38M3.93M3.10M
Gross Profit3.67M3.50M2.40M2.50M215.51K
EBITDA-5.01M-5.14M-5.58M-3.40M-989.96K
Net Income-5.91M-5.63M-6.11M-4.19M-1.01M
Balance Sheet
Total Assets9.03M8.70M13.44M18.35M20.51M
Cash, Cash Equivalents and Short-Term Investments980.76K935.50K5.21M12.33M15.60M
Total Debt961.74K128.50K284.82K14.87K46.00K
Total Liabilities2.76M1.55M1.51M1.19M387.00K
Stockholders Equity6.27M7.15M11.92M17.16M20.13M
Cash Flow
Free Cash Flow-5.38M-4.98M-5.75M-4.04M-1.17M
Operating Cash Flow-4.91M-4.53M-5.60M-3.99M-864.05K
Investing Cash Flow-473.09K-457.54K-147.74K-53.40K-301.85K
Financing Cash Flow5.43M706.43K-87.33K14.92M1.79M

Control Bionics Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.04
Price Trends
50DMA
0.03
Positive
100DMA
0.04
Positive
200DMA
0.05
Negative
Market Momentum
MACD
<0.01
Negative
RSI
79.38
Negative
STOCH
41.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:CBL, the sentiment is Positive. The current price of 0.04 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.03, and below the 200-day MA of 0.05, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 79.38 is Negative, neither overbought nor oversold. The STOCH value of 41.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:CBL.

Control Bionics Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (60)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
60
Neutral
HK$17.07B5.63-7.44%2.87%11.55%-28.15%
48
Neutral
AU$11.78M-98.08%-7.44%30.34%
47
Neutral
AU$8.98M-375.15%-59.01%17.13%
47
Neutral
AU$14.97M-61.15%35.63%18.55%
46
Neutral
AU$2.86M-117.20%2.91%13.51%
45
Neutral
€10.51M-321.94%-39.97%55.29%
38
Underperform
AU$8.96M-191.40%19.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:CBL
Control Bionics Ltd.
0.04
-0.01
-20.00%
AU:HMD
HeraMED Ltd.
0.01
>-0.01
-31.58%
AU:UCM
Uscom Limited
0.01
-0.01
-50.00%
AU:AT1
Atomo Diagnostics Ltd.
0.02
0.00
0.00%
AU:ADR
Adherium Ltd.
0.01
-0.01
-50.00%
AU:IRX
InhaleRx Limited
0.04
0.02
100.00%

Control Bionics Ltd. Corporate Events

Control Bionics Limited Announces Cessation of Securities
Jul 8, 2025

Control Bionics Limited announced the cessation of 967,720 securities due to the expiry of options or other convertible securities without exercise or conversion as of February 28, 2025. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s financial strategies and market positioning.

Control Bionics to Host Investor Webinar Amid Product Expansion
Apr 29, 2025

Control Bionics Limited announced an investor webinar to discuss its quarterly results and recent advancements. The company is enhancing its market position with innovative products like the NeuroNode and DROVE, and is expanding into new sectors with the NeuroStrip®, potentially impacting its operations and stakeholder interests.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 24, 2025